Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mistry, E. Watkins, M. Britton, M. Nordstrom (Surrey, United Kingdom). Identifying patients with severe allergic asthma who are potentially eligible for omalizumab treatment by EU licence and NICE guidance criteria. Eur Respir J 2008; 32: Suppl. 52, 2006

Member's Comments

No comment yet.

Related content which might interest you: BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Mepolizumab eligibility in children with severe asthma – do we need paediatric specific criteria? Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 The application of GINA guidelines results in a reduced number of exacerbations in asthmatic patients Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 Is mild asthma outside the guidelines? Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE) Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Are current treatment recommendations suited to elderly patients with asthma or COPD? Source: Eur Respir Mon; 2009: 43: 267–285 Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Cost of asthma in patients treated with national asthma guideline in Turkey Source: Eur Respir J 2003; 22: Suppl. 45, 481s Year: 2003 Should patients with mild asthma be excluded from allergic rhinitis drug trials? Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 From guidelines to personalized treatment of children with asthma Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Evaluation of a diagnostic–therapeutic pathway on GINA guidelines between specialist and primary care physicians. Study and result at 1 year in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008